PARP16 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Talazoparib (SCHEMBL2046086)	1.00	2/20
Talazoparib (SCHEMBL2295997)	1.00	2/20
Talazoparib (SCHEMBL2299348)	1.00	2/20
SCHEMBL2043333	0.88	2/20
SCHEMBL2312803	0.88	2/20
SCHEMBL2313537	0.88	2/20
SCHEMBL2043160	0.81	2/20
SCHEMBL2311187	0.81	2/20
SCHEMBL2314408	0.81	2/20
SCHEMBL2379944	0.81	2/20
SCHEMBL2382839	0.81	2/20
Talazoparib (SCHEMBL2717160)	0.80	2/20
SCHEMBL2051171	0.80	2/20
SCHEMBL2313547	0.80	2/20
SCHEMBL2317217	0.80	2/20
SCHEMBL2052528	0.74	2/20
SCHEMBL2053606	0.74	2/20
SCHEMBL2313059	0.74	2/20
SCHEMBL2050032	0.66	2/20
SCHEMBL2311053	0.66	2/20

Clinical trials — most relevant to PARP16 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma	PHASE2	COMPLETED
Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)	PHASE2	RECRUITING
A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL	PHASE1/PHASE2	COMPLETED
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies	PHASE1/PHASE2	RECRUITING
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA)	PHASE1/PHASE2	COMPLETED
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib	PHASE2	COMPLETED
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer	PHASE2	COMPLETED
Olaparib In Metastatic Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Phase II ABT-888 With Cyclophosphamide	PHASE2	COMPLETED
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma	PHASE2	COMPLETED
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment	PHASE2	ACTIVE_NOT_RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer	PHASE1	COMPLETED
Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer	PHASE1	UNKNOWN
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults	PHASE1	RECRUITING
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers	PHASE1	COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer	PHASE1	ACTIVE_NOT_RECRUITING
Pre-Operative Radiation and Veliparib for Breast Cancer	PHASE1	COMPLETED
Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma	PHASE1	ACTIVE_NOT_RECRUITING
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts	PHASE1	ACTIVE_NOT_RECRUITING
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors	PHASE1	ACTIVE_NOT_RECRUITING
PET Imaging of PARP Activity in Cancer	EARLY_PHASE1	UNKNOWN
Sirtuin1 in COVID19 Patients	nan	UNKNOWN
Project SIRT6 Activator	nan	RECRUITING
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer	nan	NO_LONGER_AVAILABLE

Related proteins — ESM-2 sequence neighbours (a PARP16 binder may also engage these)

Protein	Name	Similarity
Q7TMM8	—	1.000	Q7TMM8 →
Q5U2Q4	—	1.000	Q5U2Q4 →
Q3ZBT2	—	0.966	Q3ZBT2 →
Q6DDX8	—	0.966	Q6DDX8 →
A7E2V1	—	0.965	A7E2V1 →
Q91WR3	—	0.965	Q91WR3 →
E1BSI0	—	0.965	E1BSI0 →
Q6NX27	—	0.965	Q6NX27 →
Q3UD82	—	0.964	Q3UD82 →
P0C152	—	0.964	P0C152 →
Q4QQS8	—	0.964	Q4QQS8 →
Q3ULW8	—	0.964	Q3ULW8 →
Q5ZJX5	—	0.964	Q5ZJX5 →
Q5R981	—	0.964	Q5R981 →
Q7ZYP6	—	0.963	Q7ZYP6 →
Q8N1G2	—	0.963	Q8N1G2 →
B1H268	—	0.963	B1H268 →
PARP8	Protein mono-ADP-ribosyltransferase PARP8	0.963	landscape →
PARP3	Protein mono-ADP-ribosyltransferase PARP3	0.963	landscape →
P60670	—	0.963	P60670 →
Q61542	—	0.962	Q61542 →
Q95JW3	—	0.962	Q95JW3 →
Q8VCB1	—	0.962	Q8VCB1 →
Q9NVU0	—	0.962	Q9NVU0 →
Q9ESJ4	—	0.962	Q9ESJ4 →
Q28DV7	—	0.962	Q28DV7 →
P47823	—	0.962	P47823 →
Q5U2X1	—	0.962	Q5U2X1 →
Q803R5	—	0.962	Q803R5 →
O35099	—	0.962	O35099 →